Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations
- 23 March 2010
- journal article
- Published by Elsevier BV in Leukemia Research
- Vol. 34 (8), 969-973
- https://doi.org/10.1016/j.leukres.2010.02.033
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01 HL082983, U54 RR019391, K24 HL077522)
This publication has 29 references indexed in Scilit:
- Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosisHaematologica, 2009
- Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic SyndromeJournal of Clinical Oncology, 2009
- Mutations of ASXL1 gene in myeloproliferative neoplasmsLeukemia, 2009
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesBlood, 2009
- Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaBritish Journal of Haematology, 2009
- Acquired mutations in TET2 are common in myelodysplastic syndromesNature Genetics, 2009
- Mutation inTET2in Myeloid CancersNew England Journal of Medicine, 2009
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1Science, 2009
- Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AMLLeukemia, 2009
- Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia veraExperimental Hematology, 2002